FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer (Q38330339)

2 September 2017

title

FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer (English)

1 reference

2 September 2017

1 reference

João Ramalho-Carvalho

João Ramalho-Carvalho

4

0 references

Carmen Jeronimo

Carmen Jerónimo

5

0 references

Manuel R. Teixeira

Manuel R Teixeira

10

0 references

Rui Henrique

Rui Henrique

6

0 references

Ragnhild A. Lothe

9

Ragnhild A Lothe

1 reference

2 September 2017

8

Rolf I Skotheim

1 reference

2 September 2017

Paula Paulo

1

1 reference

2 September 2017

João D Barros-Silva

2

1 reference

2 September 2017

Franclim R Ribeiro

3

1 reference

2 September 2017

Guro E Lind

7

1 reference

2 September 2017

language of work or name

English

0 references

publication date

12 November 2011

1 reference

Genes, Chromosomes and Cancer

2 September 2017

published in

1 reference

2 September 2017

volume

51

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

240-249

1 reference

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

2 September 2017

cites work

1 reference

Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer.

21 January 2018

1 reference

TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications

21 January 2018

1 reference

TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions

21 January 2018

1 reference

ETS gene fusions in prostate cancer

21 January 2018

1 reference

Complex patterns of ETS gene alteration arise during cancer development in the human prostate

21 January 2018

1 reference

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort

21 January 2018

1 reference

EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma.

21 January 2018

1 reference

A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer

21 January 2018

1 reference

Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.

21 January 2018

1 reference

TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.

21 January 2018

1 reference

Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer.

21 January 2018

1 reference

Genomic and biochemical insights into the specificity of ETS transcription factors

21 January 2018

1 reference

Recurrent gene fusions in prostate cancer

21 January 2018

1 reference

Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases

21 January 2018

1 reference

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer

21 January 2018

1 reference

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion

21 January 2018

1 reference

Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene

21 January 2018

1 reference

The Biology of Ewing sarcoma.

21 January 2018

1 reference

TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.

21 January 2018

1 reference

Testing mutual exclusivity of ETS rearranged prostate cancer

21 January 2018

1 reference

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer

21 January 2018

1 reference

Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer

21 January 2018

1 reference

ETS gene fusions in prostate cancer: from discovery to daily clinical practice

21 January 2018

1 reference

Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues

21 January 2018

1 reference

Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent

21 January 2018

1 reference

Recombinant EWS-FLI1 oncoprotein activates transcription

21 January 2018

1 reference

Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer

21 January 2018

1 reference

Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo

21 January 2018

1 reference

DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis.

21 January 2018

1 reference

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

21 January 2018

1 reference

Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/GCC.20948

1 reference

2 September 2017

1 reference